TapewireFind a company

person · Reporting owner

Epstein David M.

Disclosed activity across 2 companies

Tapewire entity
34558
SEC CIK
0001488668

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Black Diamond Therapeutics, Inc.BDTX · Entity 6669Director · SEE REMARKSJune 27, 2023June 28, 2023
GYRE THERAPEUTICS, INC.GYRE · Entity 5247DirectorJune 10, 2026June 30, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Black Diamond Therapeutics, Inc.

Report date June 27, 2023 · Filed June 28, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect671,423 Reported balance After 2023-06-27 transaction · row 1
1 source row

Row 1 · 2023-06-27 · Sale · Disposed 25,000 · Balance 671,423

F1: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of December 29, 2022.

Common StockSEC Table I · non-derivativeIndirectSee footnote23,090 Reported balance Holding disclosure · report date 2023-06-27 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 23,090

F2: Shares held by wife.

Common StockSEC Table I · non-derivativeIndirectSee footnote104,449 Reported balance Holding disclosure · report date 2023-06-27 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 104,449

F3: Shares held by David M. Epstein 2019 Trust For Elle. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Elle and may be deemed to beneficially own these securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote104,449 Reported balance Holding disclosure · report date 2023-06-27 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 104,449

F4: Shares held by David M. Epstein 2019 Trust For Zoe. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Zoe and may be deemed to beneficially own these securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote16,579 Reported balance Holding disclosure · report date 2023-06-27 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 16,579

F5: Shares held by David M. Epstein 2019 Trust For Robert. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Robert and may be deemed to beneficially own these securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote16,579 Reported balance Holding disclosure · report date 2023-06-27 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 16,579

F6: Shares held by David M. Epstein 2019 Trust For Shelley. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Shelley and may be deemed to beneficially own these securities.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of December 29, 2022.

F2: Shares held by wife.

F3: Shares held by David M. Epstein 2019 Trust For Elle. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Elle and may be deemed to beneficially own these securities.

F4: Shares held by David M. Epstein 2019 Trust For Zoe. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Zoe and may be deemed to beneficially own these securities.

F5: Shares held by David M. Epstein 2019 Trust For Robert. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Robert and may be deemed to beneficially own these securities.

F6: Shares held by David M. Epstein 2019 Trust For Shelley. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Shelley and may be deemed to beneficially own these securities.

GYRE THERAPEUTICS, INC.

Report date June 10, 2026 · Filed June 30, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.95 · Expires 2036-06-10Direct40,000 Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-10 · Grant · Acquired 40,000 · Balance 40,000

F1: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 10, 2026 Filed Jun 30, 2026 22:17 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $5.95 $0.00
Disclosure

SEC source: 0001140361-26-027007 · form4.xml · derivative · entry 1

Epstein David M. · CIK 0001488668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-10

F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:22 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 GrantStock Option (Right to Buy) · Derivative 26,000 $0.00 Strike: $8.58 $0.00
Disclosure

SEC source: 0001140361-25-021792 · form4.xml · derivative · entry 1

Epstein David M. · CIK 0001488668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Common Stock · 26,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 4, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:07 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 GrantStock Option (Right to Buy) · Derivative 52,000 $0.00 Strike: $9.98 $0.00
Disclosure

SEC source: 0001140361-24-037713 · form4.xml · derivative · entry 1

Epstein David M. · CIK 0001488668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,000

Underlying: Common Stock · 52,000 shares

Expires 2034-08-14

F1 · derivative.exercise_date: This option represents a right to purchase a total of 52,000 shares of the Issuer's common stock, which will vest in 36 equal monthly installments through August 14, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Read SEC document
August 06, 2024 Filed Aug 8, 2024 20:31 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 GrantStock Option (Right to Buy) · Derivative 1,866 $0.00 Strike: $10.79 $0.00
Disclosure

SEC source: 0001140361-24-036417 · form4.xml · derivative · entry 1

Epstein David M. · CIK 0001488668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,866

Underlying: Common Stock · 1,866 shares

Expires 2034-08-06

F1 · derivative.exercise_date: These options vest as to one-third on each of the first, second and third anniversaries of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Read SEC document
June 27, 2023 Filed Jun 28, 2023 20:02 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 SaleCommon Stock 25,000 $6.70 $167,500.00
Disclosure

SEC source: 0001415889-23-010388 · form4-06282023_080616.xml · nonDerivative · entry 1

Epstein David M. · CIK 0001488668 · Director · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 671,423

F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of December 29, 2022.

Read SEC document
February 13, 2023 Filed Feb 15, 2023 21:10 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 GrantStock Option (Right to Buy) · Derivative 420,000 $0.00 Strike: $2.92 $0.00
Disclosure

SEC source: 0001104659-23-022387 · tm236831-3_4seq1.xml · derivative · entry 1

Epstein David M. · CIK 0001488668 · Director · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 420,000

Underlying: Common Stock · 420,000 shares

Expires 2033-02-12

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document
February 15, 2022 Filed Feb 17, 2022 21:19 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 GrantStock Option (Right to Buy) · Derivative 300,000 $0.00 Strike: $3.79 $0.00
Disclosure

SEC source: 0001415889-22-001517 · form4-02172022_010237.xml · derivative · entry 1

Epstein David M. · CIK 0001488668 · Director · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2032-02-14

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:46 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 GrantStock Option (Right to Buy) · Derivative 225,000 $0.00 Strike: $28.69 $0.00
Disclosure

SEC source: 0000899243-21-007431 · doc4.xml · derivative · entry 1

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2031-02-16

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:21 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 Exercise / conversionStock Option (Right to Buy) · Derivative 3,000 $0.00 Strike: $6.42 $0.00
Disclosure

SEC source: 0000899243-21-000741 · doc4.xml · derivative · entry 9

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,116

Underlying: Common Stock · 3,000 shares

Expires 2029-08-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:21 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 SaleCommon Stock 2,015 $31.80 $64,074.78
Disclosure

SEC source: 0000899243-21-000741 · doc4.xml · nonDerivative · entry 3

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 696,423

F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.55 to $32.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:21 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 SaleCommon Stock 9,985 $30.99 $309,430.16
Disclosure

SEC source: 0000899243-21-000741 · doc4.xml · nonDerivative · entry 2

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 698,438

F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.55 to $31.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:21 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 Exercise / conversionCommon Stock 3,000 $6.42 $19,260.00
Disclosure

SEC source: 0000899243-21-000741 · doc4.xml · nonDerivative · entry 1

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 708,423

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 15, 2020 Filed Dec 17, 2020 00:39 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 Exercise / conversionStock Option (Right to Buy) · Derivative 2,500 $0.00 Strike: $6.42 $0.00
Disclosure

SEC source: 0000899243-20-034186 · doc4.xml · derivative · entry 7

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,116

Underlying: Common Stock · 2,500 shares

Expires 2029-08-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document
December 15, 2020 Filed Dec 17, 2020 00:39 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 Exercise / conversionCommon Stock 2,500 $6.42 $16,050.00
Disclosure

SEC source: 0000899243-20-034186 · doc4.xml · nonDerivative · entry 1

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 705,423

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:17 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 Exercise / conversionStock Option (Right to Buy) · Derivative 3,000 $0.00 Strike: $6.42 $0.00
Disclosure

SEC source: 0000899243-20-032670 · doc4.xml · derivative · entry 9

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,616

Underlying: Common Stock · 3,000 shares

Expires 2029-08-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:17 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 SaleCommon Stock 1,077 $33.45 $36,020.80
Disclosure

SEC source: 0000899243-20-032670 · doc4.xml · nonDerivative · entry 3

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 702,923

F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.26 to $33.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:17 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 SaleCommon Stock 10,923 $32.64 $356,552.94
Disclosure

SEC source: 0000899243-20-032670 · doc4.xml · nonDerivative · entry 2

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 704,000

F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.19 to $33.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:17 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 Exercise / conversionCommon Stock 3,000 $6.42 $19,260.00
Disclosure

SEC source: 0000899243-20-032670 · doc4.xml · nonDerivative · entry 1

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 714,923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 00:56 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 Exercise / conversionStock Option (Right to Buy) · Derivative 3,000 $0.00 Strike: $6.42 $0.00
Disclosure

SEC source: 0000899243-20-030313 · doc4.xml · derivative · entry 9

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,616

Underlying: Common Stock · 3,000 shares

Expires 2029-08-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 00:56 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 SaleCommon Stock 83 $31.88 $2,645.63
Disclosure

SEC source: 0000899243-20-030313 · doc4.xml · nonDerivative · entry 3

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 711,923

F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 00:56 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 SaleCommon Stock 11,917 $31.13 $371,010.77
Disclosure

SEC source: 0000899243-20-030313 · doc4.xml · nonDerivative · entry 2

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 712,006

F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.74 to $31.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 00:56 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 Exercise / conversionCommon Stock 3,000 $6.42 $19,260.00
Disclosure

SEC source: 0000899243-20-030313 · doc4.xml · nonDerivative · entry 1

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723,923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 01, 2020 Filed Oct 2, 2020 21:07 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 Exercise / conversionStock Option (Right to Buy) · Derivative 3,000 $0.00 Strike: $6.42 $0.00
Disclosure

SEC source: 0000899243-20-026891 · doc4.xml · derivative · entry 8

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,616

Underlying: Common Stock · 3,000 shares

Expires 2029-08-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document
October 01, 2020 Filed Oct 2, 2020 21:07 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 SaleCommon Stock 12,000 $30.33 $363,962.40
Disclosure

SEC source: 0000899243-20-026891 · doc4.xml · nonDerivative · entry 2

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 720,923

F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
October 01, 2020 Filed Oct 2, 2020 21:07 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 Exercise / conversionCommon Stock 3,000 $6.42 $19,260.00
Disclosure

SEC source: 0000899243-20-026891 · doc4.xml · nonDerivative · entry 1

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 732,923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:57 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 ConversionSeries B Preferred Stock · Derivative 13,136 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-003358 · doc4.xml · derivative · entry 6

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,354 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date.

F3 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date.

F3 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date.

F3 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:57 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 ConversionSeries A Preferred Stock · Derivative 69,636 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-003358 · doc4.xml · derivative · entry 5

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 23,090 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.

F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.

F2 · ownership.nature: Shares held by wife.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:57 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 ConversionSeries A Preferred Stock · Derivative 732,560 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-003358 · doc4.xml · derivative · entry 4

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 242,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.

F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:57 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 ConversionCommon Stock 4,354 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-003358 · doc4.xml · nonDerivative · entry 3

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 729,923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:57 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 ConversionCommon Stock 23,090 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-003358 · doc4.xml · nonDerivative · entry 2

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 23,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.

F2 · ownership.nature: Shares held by wife.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:57 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 ConversionCommon Stock 242,904 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-003358 · doc4.xml · nonDerivative · entry 1

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 725,569

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.

Read SEC document
January 29, 2020 Filed Jan 31, 2020 21:51 UTC Black Diamond Therapeutics, Inc. BDTX · Entity 6669 GrantStock Option (Right to Buy) · Derivative 278,532 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-20-002442 · doc4.xml · derivative · entry 1

Epstein David M. · CIK 0001488668 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,532

Underlying: Common Stock · 278,532 shares

Expires 2030-01-29

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.